Seqalis is proud to announce its participation in a pivotal research initiative in the fight against breast cancer !
We are delighted to announce the participation of Seqalis in phase 2 of the AURORA project, led by the Breast International Group (BIG) in their pursuit of progress in breast cancer research.
In this new phase, Seqalis is playing a crucial role by sharing its expertise as a laboratory service provider. Seqalis will be focusing on IHC analysis and NGS sequencing using OncoDNA’s OncoDEEP Kit.
Being part of this collaboration, which brings together 17 hospitals from 7 research groups in 8 European countries, Seqalis and its parent company, the Institute of Pathology and Genetics, keep on demonstrating their unwavering commitment to advancing precision medicine thus making significant contribution to the field of oncology research.
We are highly grateful to the Breast International Group and to OncoDNA for entrusting us for the IHC and the NGS sequencing analysis within the scope of the AURORA 2 Project.
Together, let’s pave the way for a better future for cancer patients.
